Novo Holdings A S Has $25.27 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Novo Holdings A S lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,000,000 shares of the biopharmaceutical company's stock after acquiring an additional 36,337 shares during the period. Celldex Therapeutics accounts for approximately 1.5% of Novo Holdings A S's holdings, making the stock its 18th biggest position. Novo Holdings A S owned approximately 1.51% of Celldex Therapeutics worth $25,270,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of CLDX. Values First Advisors Inc. raised its position in Celldex Therapeutics by 20.0% during the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock valued at $733,000 after buying an additional 4,837 shares during the period. Barclays PLC lifted its position in Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after buying an additional 76,207 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 4,967 shares during the period. Invesco Ltd. increased its stake in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after acquiring an additional 871 shares during the last quarter. Finally, Sovran Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the fourth quarter worth $2,867,000.

Celldex Therapeutics Stock Performance

CLDX traded down $1.88 during trading hours on Tuesday, reaching $18.41. The company's stock had a trading volume of 351,786 shares, compared to its average volume of 882,573. The firm has a market cap of $1.22 billion, a PE ratio of -7.14 and a beta of 1.39. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The company's 50-day moving average is $19.09 and its 200-day moving average is $23.07.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CLDX. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Tuesday. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $55.30.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.